Forbion Capital Partners
Overview
Forbion is a leading global venture capital firm with deep expertise in Europe and offices in Naarden, The Netherlands, Munich, Germany and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. In addition, Forbion leverages its biotech expertise beyond human health to address 'planetary health' challenges through its BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Mestag Therapeutics | Mar 2026 | Early Funding | Co-investor |
| Slate Medicines | Feb 2026 | Series A | Lead |
| Altesa Biosciences | Feb 2026 | Series B | Lead |
| PACT | Oct 2025 | Series A | Lead |
| CellCentric | May 2025 | Series C | Lead |
Key People
Geert-Jan Mulder
Managing Partner
Martien van Osch
Managing Partner
Sander Slootweg
Co-owner And Managing Partner
Alexander Hoffmann
General Partner
Dmitrij Hristodorov
General Partner
Jasper Bos
General Partner
Nanna Lüneborg
General Partner
Wouter Joustra
General Partner
Gijs van den Brink
Operating Partner
John Montana
Operating Partner
Rory Gummerson
Operating Partner
Thomas Gundelund Rasmussen
Operating Partner
Avi Molcho
Venture Partner
Jens Wendland
Venture Partner
Jonathan McNeill
Venture Partner
Josh Brumm
Forbion Venture Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
